Palvella Therapeutics (PVLA) versus Its Peers Financial Analysis

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Palvella Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Institutional and Insider Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Palvella Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8137	21793	49588	1308	2.55

Palvella Therapeutics presently has a consensus target price of $40.33, suggesting a potential upside of 109.85%. As a group, “Pharmaceutical preparations” companies have a potential upside of 239.80%. Given Palvella Therapeutics’ peers higher possible upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Palvella Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-236.05%	-32.89%

Valuation & Earnings

This table compares Palvella Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.59
Palvella Therapeutics Competitors	$1.84 billion	$140.61 million	-7.56

Palvella Therapeutics’ peers have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Palvella Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ peers have a beta of 3.66, suggesting that their average stock price is 266% more volatile than the S&P 500.

Summary

Palvella Therapeutics peers beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.